NYXH
Closed
Nyxoah
7.55
+0.07 (+0.94%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 7.48
Day's Range: 7.41 - 7.76
Send
sign up or login to leave a comment!
When Written:
7.8
Nyxoah is a medical technology company that specializes in the development and commercialization of innovative solutions and therapies for sleep-related disorders. The company's main focus is on developing implantable neurostimulation devices that can help treat obstructive sleep apnea (OSA) and other related conditions.
Nyxoah's flagship product is the Genio® system, which is an implantable neurostimulation device that is designed to treat OSA by stimulating the hypoglossal nerve to keep the airway open during sleep. The device is implanted under the skin in the upper chest area and is controlled by a small handheld device that the patient can use to adjust the stimulation settings.
The Genio® system has received regulatory approval in Europe and is currently undergoing clinical trials in the United States. The company is also developing other neurostimulation devices and therapies for sleep-related disorders, including snoring and insomnia.
Nyxoah was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. The company has a global presence and has operations in Europe, the United States, and Asia.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Nyxoah's flagship product is the Genio® system, which is an implantable neurostimulation device that is designed to treat OSA by stimulating the hypoglossal nerve to keep the airway open during sleep. The device is implanted under the skin in the upper chest area and is controlled by a small handheld device that the patient can use to adjust the stimulation settings.
The Genio® system has received regulatory approval in Europe and is currently undergoing clinical trials in the United States. The company is also developing other neurostimulation devices and therapies for sleep-related disorders, including snoring and insomnia.
Nyxoah was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. The company has a global presence and has operations in Europe, the United States, and Asia.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
7.8
Nyxoah is a medical technology company that specializes in developing and commercializing innovative solutions for the treatment of sleep-disordered breathing. The company's flagship product is the Genio system, a small implantable device that delivers mild stimulation to the nerve that controls the tongue, helping to keep the airway open during sleep. The Genio system is designed to treat obstructive sleep apnea (OSA), a common sleep disorder that affects millions of people worldwide. Nyxoah is headquartered in Mont-Saint-Guibert, Belgium, and has operations in Europe, the United States, and Australia. The company was founded in 2009 and went public on the Brussels Euronext stock exchange in October 2020.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!